Regulatory Filings • Sep 6, 2023
Regulatory Filings
Open in ViewerOpens in native device viewer
Washington, D.C. 20549
OMB APPROVAL
Check this box if no
continue. See Instruction 1(b).
longer subject to Section 16. Form 4 or Form 5 obligations may
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| Shalev | 1. Name and Address of Reporting Person Varda |
2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Ltd. [TEVA] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ 10% Owner X Director |
|||||
|---|---|---|---|---|---|---|---|---|
| (Last) 124 Dvora HaNevi'a St. |
(First) C/O Teva Pharmaceutical Industries Ltd. |
(Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 09/02/2023 |
_ Officer (give title below)_ Other (specify below) | ||||
| (Street) Tel Aviv |
L3 | 6944020 | 4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person ____ Form filed by More than One Reporting Person |
||||
| (City) | (State) | (Zip) | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |
| 1.Title of Security | 2. Transaction | 2A. Deemed | 3. Transaction | 4. Securities Acquired | 5. Amount of Securities Beneficially | 6. | 7. Nature of | |||
|---|---|---|---|---|---|---|---|---|---|---|
| (Instr. 3) | Date | Execution Date, if | Code | (A) or Disposed of (D) | Owned Following Reported | Ownership | Indirect | |||
| (Month/Day/Year) | any | (Instr. 8) | (Instr. 3, 4 and 5) | Transaction(s) | Form: | Beneficial | ||||
| (Month/Day/Year) | (Instr. 3 and 4) | Direct (D) | Ownership | |||||||
| or Indirect | (Instr. 4) | |||||||||
| (A) or | (I) | |||||||||
| Code | V | Amount | (D) | Price | (Instr. 4) |
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
(Instr. 4) | (Instr. 4) | ||||||
| Restricted Share Units |
(1) | 09/02/2023 | A | 12,872 | (2) | (2) | Ordinary Shares (3) |
12,872 | \$ 0 |
12,872 | D |
| /s/ Dov Bergwerk as attorney-in-fact for Varda Shalev |
09/05/2023 |
|---|---|
| ---------------------------------------------------------- | ------------ |
**Signature of Reporting Person Date
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.